The disclosure relates to compositions beneficial for ruminant administration. Particularly, the disclosure provides compositions formulated for ruminants that comprise beneficial microbes.

The disclosure relates to compositions beneficial for ruminant administration. Particularly, the disclosure provides compositions formulated for ruminants that comprise beneficial microbes.

The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.

The invention encompasses therapeutic formulations comprising a protein active ingredient and a stabilizing excipient, methods of improving stability in a therapeutic formulation comprising a protein active ingredient by adding a stability-improving amount of a stabilizing excipient to the therapeutic formulation, and methods of reducing adverse infusion-related effects in a patient, comprising administering to a patient in need thereof a therapeutic formulation comprising a protein active ingredient and a stabilizing excipient.

The invention encompasses therapeutic formulations comprising a protein active ingredient and a stabilizing excipient, methods of improving stability in a therapeutic formulation comprising a protein active ingredient by adding a stability-improving amount of a stabilizing excipient to the therapeutic formulation, and methods of reducing adverse infusion-related effects in a patient, comprising administering to a patient in need thereof a therapeutic formulation comprising a protein active ingredient and a stabilizing excipient.

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and for increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methl9243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.

Synthetic H2 RLN mRNA constructs that induce expression of relaxin, methods of preparing such synthetic H2 RLN mRNA constructs, and methods of administering such constructs to mammals to facilitate delivery of offspring or methods of administering such constructs to non-pregnant mammals to facilitate procedures involving the reproductive tract.

Synthetic H2 RLN mRNA constructs that induce expression of relaxin, methods of preparing such synthetic H2 RLN mRNA constructs, and methods of administering such constructs to mammals to facilitate delivery of offspring or methods of administering such constructs to non-pregnant mammals to facilitate procedures involving the reproductive tract.

The disclosure relates to isolated microorganismsincluding novel strains of the microorganismsmicrobial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.